nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—ABCB1—Topotecan—cervical cancer	0.226	1	CbGbCtD
Dabigatran etexilate—F2—Common Pathway—SERPIND1—cervical cancer	0.0337	0.109	CbGpPWpGaD
Dabigatran etexilate—F2—Intrinsic Pathway—SERPIND1—cervical cancer	0.0287	0.0931	CbGpPWpGaD
Dabigatran etexilate—F2—Intrinsic Pathway—GP5—cervical cancer	0.0251	0.0813	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—YY1—cervical cancer	0.0201	0.0651	CbGpPWpGaD
Dabigatran etexilate—F2—Formation of Fibrin Clot (Clotting Cascade)—SERPIND1—cervical cancer	0.0194	0.0628	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—female reproductive system—cervical cancer	0.018	0.0479	CbGeAlD
Dabigatran etexilate—UGT1A9—renal system—cervical cancer	0.0171	0.0453	CbGeAlD
Dabigatran etexilate—F2—Formation of Fibrin Clot (Clotting Cascade)—GP5—cervical cancer	0.0169	0.0549	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.0166	0.0537	CbGpPWpGaD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.0162	0.0525	CbGpPWpGaD
Dabigatran etexilate—CES2—uterine cervix—cervical cancer	0.0147	0.039	CbGeAlD
Dabigatran etexilate—CES2—decidua—cervical cancer	0.014	0.0372	CbGeAlD
Dabigatran etexilate—CES2—renal system—cervical cancer	0.0138	0.0365	CbGeAlD
Dabigatran etexilate—UGT2B7—renal system—cervical cancer	0.0138	0.0365	CbGeAlD
Dabigatran etexilate—F2—epithelium—cervical cancer	0.0133	0.0353	CbGeAlD
Dabigatran etexilate—CES2—endometrium—cervical cancer	0.0133	0.0353	CbGeAlD
Dabigatran etexilate—NQO2—uterine cervix—cervical cancer	0.0131	0.0349	CbGeAlD
Dabigatran etexilate—F2—Complement and Coagulation Cascades—SERPIND1—cervical cancer	0.0131	0.0423	CbGpPWpGaD
Dabigatran etexilate—CES2—mammalian vulva—cervical cancer	0.0129	0.0341	CbGeAlD
Dabigatran etexilate—NQO2—decidua—cervical cancer	0.0125	0.0332	CbGeAlD
Dabigatran etexilate—F2—renal system—cervical cancer	0.0123	0.0327	CbGeAlD
Dabigatran etexilate—NQO2—renal system—cervical cancer	0.0123	0.0326	CbGeAlD
Dabigatran etexilate—CES2—uterus—cervical cancer	0.0123	0.0325	CbGeAlD
Dabigatran etexilate—NQO2—endometrium—cervical cancer	0.0119	0.0315	CbGeAlD
Dabigatran etexilate—CES1—E2F transcription factor network—YY1—cervical cancer	0.0118	0.0383	CbGpPWpGaD
Dabigatran etexilate—NQO2—mammalian vulva—cervical cancer	0.0115	0.0305	CbGeAlD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.0113	0.0367	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—female reproductive system—cervical cancer	0.011	0.0292	CbGeAlD
Dabigatran etexilate—CES2—female reproductive system—cervical cancer	0.011	0.0292	CbGeAlD
Dabigatran etexilate—NQO2—uterus—cervical cancer	0.0109	0.0291	CbGeAlD
Dabigatran etexilate—CES2—female gonad—cervical cancer	0.01	0.0266	CbGeAlD
Dabigatran etexilate—CES2—vagina—cervical cancer	0.00996	0.0264	CbGeAlD
Dabigatran etexilate—F2—female reproductive system—cervical cancer	0.00988	0.0262	CbGeAlD
Dabigatran etexilate—NQO2—female reproductive system—cervical cancer	0.00984	0.0261	CbGeAlD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—SMUG1—cervical cancer	0.00956	0.031	CbGpPWpGaD
Dabigatran etexilate—CES1—female reproductive system—cervical cancer	0.00907	0.0241	CbGeAlD
Dabigatran etexilate—F2—female gonad—cervical cancer	0.00899	0.0239	CbGeAlD
Dabigatran etexilate—NQO2—female gonad—cervical cancer	0.00895	0.0238	CbGeAlD
Dabigatran etexilate—NQO2—vagina—cervical cancer	0.0089	0.0236	CbGeAlD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—GP6—cervical cancer	0.00863	0.0279	CbGpPWpGaD
Dabigatran etexilate—CES1—female gonad—cervical cancer	0.00825	0.0219	CbGeAlD
Dabigatran etexilate—F2—PAR1-mediated thrombin signaling events—AKAP13—cervical cancer	0.00763	0.0247	CbGpPWpGaD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—MTHFR—cervical cancer	0.00669	0.0216	CbGpPWpGaD
Dabigatran etexilate—CES2—lymph node—cervical cancer	0.00644	0.0171	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—cervical cancer	0.00576	0.0153	CbGeAlD
Dabigatran etexilate—CES1—lymph node—cervical cancer	0.00531	0.0141	CbGeAlD
Dabigatran etexilate—Hyperbilirubinaemia—Topotecan—cervical cancer	0.00525	0.0592	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Topotecan—cervical cancer	0.00505	0.0569	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.00454	0.0147	CbGpPWpGaD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—TP53—cervical cancer	0.00431	0.0139	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.00397	0.0128	CbGpPWpGaD
Dabigatran etexilate—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00312	0.0352	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00306	0.0345	CcSEcCtD
Dabigatran etexilate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.00293	0.00948	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—MTHFR—cervical cancer	0.00291	0.00941	CbGpPWpGaD
Dabigatran etexilate—ABCB1—epithelium—cervical cancer	0.00286	0.00759	CbGeAlD
Dabigatran etexilate—ABCB1—uterine cervix—cervical cancer	0.00284	0.00753	CbGeAlD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—HES1—cervical cancer	0.00272	0.00882	CbGpPWpGaD
Dabigatran etexilate—ABCB1—decidua—cervical cancer	0.0027	0.00717	CbGeAlD
Dabigatran etexilate—Pneumonia—Topotecan—cervical cancer	0.00269	0.0303	CcSEcCtD
Dabigatran etexilate—Infestation—Topotecan—cervical cancer	0.00267	0.0301	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Topotecan—cervical cancer	0.00267	0.0301	CcSEcCtD
Dabigatran etexilate—ABCB1—renal system—cervical cancer	0.00265	0.00704	CbGeAlD
Dabigatran etexilate—ABCB1—endometrium—cervical cancer	0.00256	0.00681	CbGeAlD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—TP53—cervical cancer	0.00254	0.00822	CbGpPWpGaD
Dabigatran etexilate—Hepatobiliary disease—Topotecan—cervical cancer	0.00253	0.0285	CcSEcCtD
Dabigatran etexilate—Epistaxis—Topotecan—cervical cancer	0.00252	0.0284	CcSEcCtD
Dabigatran etexilate—ABCB1—mammalian vulva—cervical cancer	0.00248	0.00659	CbGeAlD
Dabigatran etexilate—Haemoglobin—Topotecan—cervical cancer	0.00241	0.0272	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Topotecan—cervical cancer	0.0024	0.027	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—MTHFR—cervical cancer	0.00237	0.00766	CbGpPWpGaD
Dabigatran etexilate—ABCB1—uterus—cervical cancer	0.00236	0.00627	CbGeAlD
Dabigatran etexilate—F2—Hemostasis—GP6—cervical cancer	0.00234	0.00757	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SERPIND1—cervical cancer	0.00234	0.00757	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.00228	0.00737	CbGpPWpGaD
Dabigatran etexilate—Angiopathy—Topotecan—cervical cancer	0.00218	0.0245	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Topotecan—cervical cancer	0.00217	0.0244	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Topotecan—cervical cancer	0.00216	0.0244	CcSEcCtD
Dabigatran etexilate—ABCB1—female reproductive system—cervical cancer	0.00212	0.00564	CbGeAlD
Dabigatran etexilate—Malnutrition—Topotecan—cervical cancer	0.00209	0.0235	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—GP5—cervical cancer	0.00204	0.00662	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.00203	0.00656	CbGpPWpGaD
Dabigatran etexilate—Back pain—Topotecan—cervical cancer	0.00202	0.0228	CcSEcCtD
Dabigatran etexilate—ABCB1—female gonad—cervical cancer	0.00193	0.00513	CbGeAlD
Dabigatran etexilate—Anaemia—Topotecan—cervical cancer	0.00193	0.0218	CcSEcCtD
Dabigatran etexilate—ABCB1—vagina—cervical cancer	0.00192	0.0051	CbGeAlD
Dabigatran etexilate—Angioedema—Topotecan—cervical cancer	0.00191	0.0215	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—MTHFR—cervical cancer	0.00188	0.00608	CbGpPWpGaD
Dabigatran etexilate—Cough—Topotecan—cervical cancer	0.00182	0.0205	CcSEcCtD
Dabigatran etexilate—Chest pain—Topotecan—cervical cancer	0.00178	0.02	CcSEcCtD
Dabigatran etexilate—Arthralgia—Topotecan—cervical cancer	0.00178	0.02	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00176	0.0199	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—TAAR6—cervical cancer	0.00173	0.00561	CbGpPWpGaD
Dabigatran etexilate—Anaphylactic shock—Topotecan—cervical cancer	0.0017	0.0192	CcSEcCtD
Dabigatran etexilate—Infection—Topotecan—cervical cancer	0.00169	0.0191	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Topotecan—cervical cancer	0.00167	0.0188	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Topotecan—cervical cancer	0.00167	0.0188	CcSEcCtD
Dabigatran etexilate—Skin disorder—Topotecan—cervical cancer	0.00165	0.0187	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00155	0.0175	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Topotecan—cervical cancer	0.00152	0.0171	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Topotecan—cervical cancer	0.0015	0.0169	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Topotecan—cervical cancer	0.00147	0.0166	CcSEcCtD
Dabigatran etexilate—Fatigue—Topotecan—cervical cancer	0.00147	0.0166	CcSEcCtD
Dabigatran etexilate—Constipation—Topotecan—cervical cancer	0.00146	0.0164	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Topotecan—cervical cancer	0.00139	0.0157	CcSEcCtD
Dabigatran etexilate—Urticaria—Topotecan—cervical cancer	0.00135	0.0153	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—WNT2—cervical cancer	0.00135	0.00438	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Topotecan—cervical cancer	0.00135	0.0152	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Topotecan—cervical cancer	0.00125	0.0142	CcSEcCtD
Dabigatran etexilate—ABCB1—lymph node—cervical cancer	0.00124	0.0033	CbGeAlD
Dabigatran etexilate—Asthenia—Topotecan—cervical cancer	0.00122	0.0138	CcSEcCtD
Dabigatran etexilate—Pruritus—Topotecan—cervical cancer	0.00121	0.0136	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Topotecan—cervical cancer	0.00117	0.0131	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—FGFR3—cervical cancer	0.00113	0.00365	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Topotecan—cervical cancer	0.00113	0.0127	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-DPB1—cervical cancer	0.00109	0.00354	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Topotecan—cervical cancer	0.00108	0.0122	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—cervical cancer	0.00108	0.0035	CbGpPWpGaD
Dabigatran etexilate—Rash—Topotecan—cervical cancer	0.00107	0.0121	CcSEcCtD
Dabigatran etexilate—Dermatitis—Topotecan—cervical cancer	0.00107	0.0121	CcSEcCtD
Dabigatran etexilate—Headache—Topotecan—cervical cancer	0.00107	0.012	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—WNT5A—cervical cancer	0.00103	0.00332	CbGpPWpGaD
Dabigatran etexilate—Nausea—Topotecan—cervical cancer	0.00101	0.0114	CcSEcCtD
Dabigatran etexilate—F2—GPCR downstream signaling—TAAR6—cervical cancer	0.000979	0.00317	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CA9—cervical cancer	0.000949	0.00307	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—TP53—cervical cancer	0.000898	0.00291	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—TAAR6—cervical cancer	0.000889	0.00288	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-DQB1—cervical cancer	0.000853	0.00276	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.00082	0.00265	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000736	0.00238	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—WNT2—cervical cancer	0.000694	0.00225	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKAP13—cervical cancer	0.000671	0.00217	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKAP13—cervical cancer	0.00061	0.00197	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—EGFR—cervical cancer	0.000558	0.00181	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CASP8—cervical cancer	0.000557	0.0018	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—WNT5A—cervical cancer	0.000526	0.0017	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TAAR6—cervical cancer	0.000525	0.0017	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CA9—cervical cancer	0.000432	0.0014	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CASP3—cervical cancer	0.000422	0.00137	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.000416	0.00135	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—WNT2—cervical cancer	0.00041	0.00133	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—MTHFR—cervical cancer	0.000385	0.00125	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKAP13—cervical cancer	0.00036	0.00117	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CA9—cervical cancer	0.000351	0.00114	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—WNT5A—cervical cancer	0.000311	0.00101	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000275	0.00089	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH2—cervical cancer	0.000218	0.000706	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—cervical cancer	0.000208	0.000674	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000208	0.000674	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000201	0.000649	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HES1—cervical cancer	0.000179	0.000579	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—cervical cancer	0.000176	0.00057	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MTHFR—cervical cancer	0.000175	0.000568	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA9—cervical cancer	0.000161	0.000521	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000159	0.000514	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TERT—cervical cancer	0.000157	0.000507	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGFR3—cervical cancer	0.000144	0.000466	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MTHFR—cervical cancer	0.000142	0.000461	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH1—cervical cancer	0.000135	0.000437	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000133	0.000432	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EGFR—cervical cancer	0.00012	0.00039	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MTOR—cervical cancer	0.000101	0.000328	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP3—cervical cancer	9.31e-05	0.000301	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—cervical cancer	8.97e-05	0.00029	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT3—cervical cancer	7.82e-05	0.000253	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGFR—cervical cancer	7.11e-05	0.00023	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTHFR—cervical cancer	6.54e-05	0.000212	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—cervical cancer	5.97e-05	0.000193	CbGpPWpGaD
